Survival outcomes of hypomethylating agents maintenance therapy in new diagnosed AML patients: Real experience data

Karakuş, Volkan; Maral, Senem; Kaya, Egemen; Gemici, Aliihsan; Dere, Yelda; Sevindik, Ömür Gökmen

Survival outcomes of hypomethylating agents maintenance therapy in new diagnosed AML patients: Real experience data

dc.authorid	0000-0002-3385-8359
dc.authorid	0000-0001-9636-4113
dc.contributor.author	Karakuş, Volkan
dc.contributor.author	Maral, Senem
dc.contributor.author	Kaya, Egemen
dc.contributor.author	Gemici, Aliihsan
dc.contributor.author	Dere, Yelda
dc.contributor.author	Sevindik, Ömür Gökmen
dc.date.accessioned	2022-10-31T09:36:16Z
dc.date.available	2022-10-31T09:36:16Z
dc.date.issued	2022
dc.department	İstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstract	OBJECTIVE: Acute myeloid leukemia (AML) is a hematological malignancy that frequently affects elderly population. With introducing the hypomethylating agents (HMAs) in elderly AML treatment, survival rates and quality of life have improved. However, long-term management in elderly and frail patients is still a challenge. In the present study, we aimed to determine whether HMA maintenance therapy is required until disease progression in frail and elderly AML patients by examining with a real-life data.METHODS: In a multicenter study, we analyzed non-promyelocytic elderly AML patients who were treated with first-line azacitidine or decitabine monotherapy in two different groups, retrospectively. While patients were treated with HMA until progression in the maintenance group, 6+3 cycles of azacitidine or decitabine were administered as a standard care of elderly AML patients in the non-maintenance group. Survival outcomes were compared between the groups.RESULTS: HMA therapy was maintained until progression in 20 patients, and HMA therapy was terminated after 6+3 cycles in 21 patients. Patients received a median of 6 (1-14) HMA cycles during follow-up time. The median 7.5 months of overall survival were observed (2-17 months) in maintenance and 3 months (1-13 months) in non-maintenance groups (p=0.001).CONCLUSION: Despite long-term exposure to HMA may appear as a risk factor for complications and toxicities in elderly and frail AML patients, the maintenance of therapy until disease progression provides a significant survival advantage. Therefore, we suggest that HMA therapy should continue until disease progression regardless the sort of HMA.
dc.identifier.citation	Karakuş, V., Maral, S., Kaya, E., Gemici, A., Dere, Y. ve Sevindik, Ö. G. (2022). Survival outcomes of hypomethylating agents maintenance therapy in new diagnosed AML patients: Real experience data. Northern Clinics of Istanbul, 9(4), 331-336. https://doi.org/10.14744/nci.2021.42800
dc.identifier.doi	10.14744/nci.2021.42800
dc.identifier.endpage	336
dc.identifier.issn	2148-4902
dc.identifier.issn	2536-4553
dc.identifier.issue	4
dc.identifier.pmid	36276561
dc.identifier.scopus	2-s2.0-85164768023
dc.identifier.scopusquality	N/A
dc.identifier.startpage	331
dc.identifier.trdizinid	1130076
dc.identifier.uri	https://doi.org/10.14744/nci.2021.42800
dc.identifier.uri	https://hdl.handle.net/20.500.12511/9897
dc.identifier.volume	9
dc.identifier.wos	000864526600007	en_US
dc.identifier.wosquality	N/A
dc.indekslendigikaynak	Web of Science
dc.indekslendigikaynak	Scopus
dc.indekslendigikaynak	TR-Dizin
dc.indekslendigikaynak	PubMed
dc.institutionauthor	Gemici, Aliihsan
dc.institutionauthor	Sevindik, Ömür Gökmen
dc.language.iso	en
dc.publisher	Kare Publishing
dc.relation.ispartof	Northern Clinics of Istanbul	en_US
dc.relation.publicationcategory	Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rights	info:eu-repo/semantics/openAccess
dc.subject	Acute Myeloid Leukemia
dc.subject	Azacitidine
dc.subject	Decitabine
dc.subject	Hypomethylating Agents
dc.title	Survival outcomes of hypomethylating agents maintenance therapy in new diagnosed AML patients: Real experience data
dc.type	Article